Consolidated revenue from operations stood at Rs. 111.05 crore
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Diversifying its portfolio to include late-phase antiviral agent
Subscribe To Our Newsletter & Stay Updated